Hostname: page-component-5c6d5d7d68-wp2c8 Total loading time: 0 Render date: 2024-08-16T04:30:25.587Z Has data issue: false hasContentIssue false

Applications for Magnetic Resonance Imaging in Bipolar Disorder

Published online by Cambridge University Press:  07 November 2014

Perry F. Renshaw*
Affiliation:
Dr. Renshaw is director of the McLean Hospital Brain Imaging Center and professor of psychiatry at, Harvard Medical School, in Boston, Massachusetts

Abstract

Bipolar disorder is a prevalent psychiatric disorder with a high rate of misdiagnosis and evidence of degenerative progression. Research indicates that the interval between bipolar episodes decreases steadily until the patient settles into a relatively frequent course of mania and depression. Various imaging techniques have been used in the understanding of the brain pathology underlying bipolar disorder through identification of patterns consistent with disruption of the normal brain activity in bipolar patients. These techniques have demonstrated evidence of abnormalities in the structure and function of the prefrontal cortex. In addition, the cerebellar vermis, which serves as an error-detection function to modulate the iterative network, appears to shrink with recurrent episodes. Functional imaging demonstrates that the anterior limbic network is overactivated and overresponsive in patients with bipolar disorder. In many patients, those deficits are often compensated for by activation of other brain areas. Ultimately, when the compensation fails, expression of bipolar symptoms arise. Using magnetic resonance spectroscopy, simple models can be constructed based on the hypothesis that mitochondrial function may be impaired in bipolar disorder. There is also increasing evidence that psychotropic medications can affect specific brain regions that are thought to be involved in the pathogenesis of psychiatric disorders. Glutamate levels appear to be elevated in untreated patients with bipolar disorder, which may cause glutamatergic neurotoxicity and negative therapeutic implications. Further advances in brain imaging may contribute to the improvement of available therapies and the understanding which treatments will be most suitable for specific patients.

Type
Research Article
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Konradi, C, Eaton, M, MacDonald, ML, Walsh, J, Benes, FM, Heckers, S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry. 2004;61(3):300308. Erratum in: Arch Gen Psychiatry. 2004;61(6):538.CrossRefGoogle ScholarPubMed
2.Stork, C, Renshaw, PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry. 2005;10(10):900919.CrossRefGoogle ScholarPubMed
3.Dager, SR, Friedman, SD, Parow, A, et al.Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry. 2004;61(5):450458.CrossRefGoogle ScholarPubMed
4.Friedman, SD, Dager, SR, Parow, A, et al.Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. Biol Psychiatry. 2004;56(5):340348.CrossRefGoogle ScholarPubMed
5.Eliassen, JC, Adler, CM, Yurgelun-Todd, D, et al.Changes in fMRI brain activation in frequently relapsing bipolar patients created with long-acting injectable risperidone. Biol Psychiatry. 2006;59:97S.Google Scholar
6.Olson, DP, Ross, A, Strakowski, SM, et al.Altered metabolite concentrations in the brains of frequently relapsing bipolar patients treated with long-acting injectable (LAI) risperidone. Biol Psychiatry. 2006;59:71S.Google Scholar
7.DelBello, MP, Cecil, KM, Adler, CM, Daniels, JP, Strakowski, SM. Neurochemical effects of olanzapine in first-hospitalization manic adolescents: a proton magnetic resonance spectroscopy study. Neuropsychopharmacology. 2006;31(6):12641273.CrossRefGoogle ScholarPubMed
8.Lyoo, IK, Sung, YH, Dager, SR, et al.Regional cerebral cortical thinning in bipolar disorder. Bipolar Disord. 2006;8(1):6574.CrossRefGoogle ScholarPubMed
9.Lieberman, JA, Tollefson, GD, Charles, C, et al.Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005;62(4):361370.CrossRefGoogle ScholarPubMed
10.Michael, N, Erfurth, A, Ohrmann, P, et al.Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex. Psychopharmacology (Berl). 2003;168(3):344346.CrossRefGoogle ScholarPubMed
11.Chang, K, Adleman, N, Kienes, K, Barnea-Goraly, Reis, A, Ketter, T. Decreased N-acetylaspartate in children with familial bipolar disorder. Biol Psychiatry. 2003;53:10591065.CrossRefGoogle ScholarPubMed
12.Winsberg, ME, Sachs, N, Tate, DL, et al.Decreased dorsolateral prefrontal N-acetylaspartate in bipolar disorder. Biol Psychiatry. 2000;47(6):207212.CrossRefGoogle Scholar
13.Moore, CM, Breeze, JL, Gruber, SA, et al.Choline, myo-inositol and mood in bipolar disorder: a proton magnetic resonance spectroscopic imaging study of the anterior cingulated cortex. Bipolar Disord. 2000;2:207216.CrossRefGoogle Scholar
14.Secades, JJ, Frontera, G. CDP-choline: pharmacological and clinical review. Methods Find Exp Clin Pharmacol. 1995 Oct;17 Suppl B:154.Google ScholarPubMed
15.Colcombe, SJ, Erickso, KI, Scalf, PE, et al.Aerobic exercise training increases brain volume in aging humans. J Gerontol A Biol Sci Med Sci. 2006 Nov;61(11):11661170.CrossRefGoogle ScholarPubMed
16.Lyoo, IK, Yoon, SJ, Cohen, B, Renshaw, PF. Efficacy of adjunctive cytidine supplementation in treating bipolar depression. Under review.Google Scholar